Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.75 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MPO | P05164 | 4/20 | 0.57 |
| ▸ | TPO | P07202 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562472 | 0.96 | PDE4A (0.69) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1373494 | 0.92 | PDE4A (0.74) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1774520 | 0.86 | PDE4A (0.56) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7990332 | 0.86 | PDE4A (0.58) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7602847 | 0.86 | PDE4A (1.00) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1958859 | 0.85 | PDE4A (0.59) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL10180927 | 0.83 | MPO (0.60) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL1461123 | 0.82 | PDE4A (0.57) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL27745079 | 0.82 | PDE4A (0.52) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL8005197 | 0.81 | ADORA2B (0.59) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | claimed |
| CN-105687199-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2016-06-22 | — | — | CN | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| CN-103638029-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | ASTRAZENECA AB | 2014-03-19 | — | — | CN | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| JP-4649112-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| CN-101873857-A | MPO inhibitors for the treatment of Huntington's disease and multiple system atrophy | ASTRAZENECA AB | 2010-10-27 | — | — | CN | claimed |
| EP-2200616-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | claimed |
| WO-2009025618-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| CN-100379737-C | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-04-09 | — | — | CN | claimed |
| CN-101062037-A | Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | claimed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | claimed |
| JP-2005526836-A | — | — | 2005-09-08 | — | — | JP | claimed |
| CN-1646531-A | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | CN | claimed |
| EP-1499613-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | claimed |
| CN-113633641-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021013942-A1 | USE OF MYELOPEROXIDASE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS SUFFERING FROM MYELOPROLIFERATIVE NEOPLASMS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-01-28 | — | — | WO | disclosed |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2020-12-31 | — | — | US | disclosed |
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | ASTRAZENECA AB (SE) | 2020-09-15 | — | — | US | disclosed |
| WO-2020021300-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-01-30 | — | — | WO | disclosed |
| US-20190099423-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2019-04-04 | — | — | US | disclosed |
| CN-105687199-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | 阿斯利康(瑞典)有限公司 | 2016-06-22 | — | — | CN | disclosed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | disclosed |
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2014-07-17 | — | — | US | disclosed |
| US-8765126-B2 | Methods of treating complications and disorders associated with G-CSF administration | SACKSTEIN ROBERT (US) | 2014-07-01 | — | — | US | disclosed |
| CN-103638029-A | MPO inhibitors for the treatment of huntington's disease and multiple system atrophy | ASTRAZENECA AB | 2014-03-19 | — | — | CN | disclosed |
| US-20130224217-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | SACKSTEIN ROBERT (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | disclosed |
| US-8236951-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2012-08-07 | — | — | US | disclosed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| EP-2332541-A1 | Use of thioxanthine derivatives as MPO inhibitors | AstraZeneca AB (SE) | 2011-06-15 | — | — | EP | disclosed |
| CN-101062037-B | Process for their preparation of thioxanthine derivatives, their use | ASTRAZENECA AB | 2011-05-25 | — | — | CN | disclosed |
| CN-101873857-A | MPO inhibitors for the treatment of Huntington's disease and multiple system atrophy | ASTRAZENECA AB | 2010-10-27 | — | — | CN | disclosed |
| EP-2200616-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | AstraZeneca AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009025617-A1 | COMBINATIONS CONTAINING MPO INHIBITORS AGAINST NEUROINFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090053176-A1 | New Combination 937 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009025618-A1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-7425560-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| CN-100379737-C | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-04-09 | — | — | CN | disclosed |
| CN-101062037-A | Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | disclosed |
| CN-1646531-A | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | CN | disclosed |
| EP-1499613-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003089430-A1 | THIOXANTHINE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199316-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | PDE4A 1525/4885ADORA2A 2145/4885PDE4B 1547/4885 |
| US-10772890-B2 | Use of myeloperoxidase (MPO) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (MSA) 938 | MPO, CAT, SOD1 | PDE4A 483/4885ADORA2A 2741/4885PDE4B 835/4885 |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 814/4885ADORA2A 3637/4885PDE4B 1209/4885 |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | PDE4A 793/4885ADORA2A 656/4885PDE4B 958/4885 |
| US-20200405724-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 548/4885ADORA2A 3016/4885PDE4B 977/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 814/4885ADORA2A 3637/4885PDE4B 1209/4885 |
| US-20130224217-A1 | METHODS OF TREATING COMPLICATIONS AND DISORDERS ASSOCIATED WITH G-CSF ADMINISTRATION | MPO, CSF3R, CSF1R | PDE4A 1525/4885ADORA2A 2145/4885PDE4B 1547/4885 |
| US-20090053176-A1 | New Combination 937 | MPO, PARK7, CAT | PDE4A 184/4885ADORA2A 2836/4885PDE4B 150/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | PDE4A 793/4885ADORA2A 656/4885PDE4B 958/4885 |
| US-20190099423-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSTEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 548/4885ADORA2A 3016/4885PDE4B 977/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | PDE4A 429/4885ADORA2A 2044/4885PDE4B 665/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | PDE4A 814/4885ADORA2A 3637/4885PDE4B 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.